[CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This study was conducted to evaluate the 2-year progression free survival rate of elderly
patients with primary CNS lymphoma followed by combination of rituximab and methotrexate
followed by rituximab and cytarabine.